Golgi Neurosciences announces Acousia Therapeutics receiving the approval for Phase 2 clinical trials

Milan (Italy) – Golgi Neurosciences Srl is proud to announce that its portfolio company Acousia Therapeutics GmbH, a clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, has received the approval form the German regulatory authorities to start Phase 2 clinical trials cisplatin-induced hearing loss of the etiology-agnostic otoprotectant ACOU085 in patients with cisplatin-induced hearing loss.

For more information, please visit Acousia Theraputics web site or Golgi Neurosciences Linkedin page.